拉喹莫德治疗原发进展型多发性硬化的随机安慰剂对照2期试验
ARPEGGIO研究将374例原发进展型多发性硬化患者随机分配至拉喹莫德0.6mg、1.5mg或安慰剂组,主要终点第48周脑容积变化百分比无显著差异(校正均差0.016%,p=0.903)。拉喹莫德0.6mg减少新发T2病灶(风险比0.4,95%CI 0.26-0.69,p=0.001),但不良事件发生率较高(83% vs 66% vs 78%)。
要点
- 拉喹莫德0.6mg未显著改善原发进展型多发性硬化患者第48周脑容积变化。
- 拉喹莫德0.6mg显著减少新发T2脑病灶,风险比0.4。
- 拉喹莫德1.5mg组因心血管事件于2016年1月1日终止。
核心结论
- 拉喹莫德0.6mg对原发进展型多发性硬化患者第48周脑容积变化无显著治疗效应,但耐受性良好。
研究设计与样本
- 随机、双盲、安慰剂对照的2期研究ARPEGGIO,纳入374例原发进展型多发性硬化患者,按1:1:1随机接受每日口服拉喹莫德0.6mg、1.5mg或安慰剂。
主要发现
- 第48周脑容积变化百分比(主要终点)在拉喹莫德0.6mg与安慰剂间无显著差异(校正均差0.016%,p=0.903)。
- 拉喹莫德0.6mg减少第48周新发T2脑病灶(风险比0.4;95%CI 0.26-0.69;p=0.001)。
- 不良事件发生率:拉喹莫德0.6mg组83%,1.5mg组66%,安慰剂组78%。
关键数值与推荐
- 主要终点脑容积变化百分比校正均差0.016%(p=0.903),未达统计学显著。
- 新发T2病灶风险比0.4(95%CI 0.26-0.69;p=0.001),支持拉喹莫德0.6mg的影像学效应。
临床怎么用
- 拉喹莫德0.6mg虽减少新发T2病灶,但未显著延缓脑萎缩,不支持用于原发进展型多发性硬化的疾病修饰治疗。
局限性
- 拉喹莫德1.5mg组因心血管事件提前终止,高剂量组数据不完整。
- 2期研究样本量有限,主要终点未达显著,需进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate efficacy, safety, and tolerability of laquinimod in patients with primary progressive multiple sclerosis (PPMS). METHODS: In the randomized, double-blind, placebo-controlled, phase 2 study, ARPEGGIO (A Randomized Placebo-controlled Trial Evaluating Laquinimod in PPMS, Gauging Gradations in MRI and Clinical Outcomes), eligible patients with PPMS were randomized 1:1:1 to receive once-daily oral laquinimod 0.6 mg or 1.5 mg or matching placebo. Percentage brain volume change (PBVC; primary endpoint) from baseline to week 48 was assessed by MRI. Secondary and exploratory endpoints included clinical and MRI measures. Efficacy endpoints were evaluated using a predefined, hierarchical statistical testing procedure. Safety was monitored throughout the study. The laquinimod 1.5 mg dose arm was discontinued on January 1, 2016, due to findings of cardiovascular events. RESULTS: A total of 374 patients were randomized to laquinimod 0.6 mg (n = 139) or 1.5 mg (n = 95) or placebo (n = 140). ARPEGGIO did not meet the primary endpoint of significant treatment effect with laquinimod 0.6 mg vs placebo on PBVC from baseline to week 48 (adjusted mean difference = 0.016%, p = 0.903). Laquinimod 0.6 mg reduced the number of new T2 brain lesions at week 48 (risk ratio 0.4; 95% confidence interval, 0.26-0.69; p = 0.001). Incidence of adverse events was higher among patients treated with laquinimod 0.6 mg (83%) vs laquinimod 1.5 mg (66%) and placebo (78%). CONCLUSIONS: Laquinimod 0.6 mg did not demonstrate a statistically significant effect on brain volume loss in PPMS at week 48. CLINICALTRIALSGOV IDENTIFIER: NCT02284568. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that, although well tolerated, laquinimod 0.6 mg did not demonstrate a significant treatment effect on PBVC in patients with PPMS.
引用
- Giovannoni G, Knappertz V, Steinerman JR, et al. A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. Neurology. 2020. PMID: 32651286. doi:10.1212/WNL.0000000000010284
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。